# Trial Of Pembrolizumab And Nintedanib

> **NCT02856425** · PHASE1 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 196 (actual)

## Conditions studied

- Patients With Any Advanced Solid Tumors

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02856425
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-10
- **Primary completion:** 2025-01-10
- **Final completion:** 2026-01-10
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02856425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02856425, "Trial Of Pembrolizumab And Nintedanib". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT02856425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*